Weinberger Paul M, Adam Bao-Ling, Gourin Christine G, Moretz William H, Bollag Roni J, Wang Beverly Y, Liu Zhongmin, Lee Jeffrey R, Terris David J
Department of Otolaryngology, Medical College of Georgia, Augusta, GA 30912, USA.
Arch Otolaryngol Head Neck Surg. 2007 May;133(5):503-10. doi: 10.1001/archotol.133.5.503.
To characterize the localization of galectin-3 in benign and malignant thyroid neoplasms and to correlate this with alterations in beta-catenin and cyclin D1 expression.
Immunohistochemical study of 116 paraffin-embedded archival specimens from 113 patients who had undergone thyroidectomy and tissue placed into a commercially available tissue microarray.
Tertiary care hospital.
Thyroid tissue microarrays were stained by standard immunohistochemical protocols with monoclonal antibodies against galectin-3, beta-catenin, and cyclin D1.
Nuclear and cytoplasmic expression of galectin-3 was correlated with clinical parameters, beta-catenin, and cyclin D1 expression.
Both cytoplasmic (56%) and nuclear (42%) galectin-3 expression was observed in most malignant neoplasms but was absent in benign thyroid specimens (P<.001). Among carcinomas, cytoplasmic galectin-3 expression was observed in papillary thyroid carcinomas (82%) and follicular (33%) and medullary (9%) carcinomas but was absent in anaplastic carcinomas (P<.001). Galectin-3 nuclear expression was observed in papillary thyroid carcinomas (62%) and follicular carcinomas (33%) but was undetectable in medullary, anaplastic carcinomas (P<.001). Cytoplasmic but not nuclear galectin-3 was inversely correlated with American Joint Committee on Cancer TNM stage (P = .02). There was a strong correlation between cytoplasmic and nuclear beta-catenin expression and both nuclear (P = .04) and cytoplasmic (P = .003) galectin-3 expression. Similarly, there was a strong association between galectin-3 nuclear (P<.001) and cytoplasmic (P<.001) expression and cyclin D1 expression.
Cytoplasmic and nuclear galectin-3 expression seem to be associated with activation of the Wnt-signaling pathway in well-differentiated thyroid neoplasms, suggesting that galectin-3 plays a role in thyroid carcinogenesis.
明确半乳糖凝集素-3在甲状腺良恶性肿瘤中的定位，并将其与β-连环蛋白和细胞周期蛋白D1表达的改变相关联。
对113例行甲状腺切除术患者的116份石蜡包埋存档标本进行免疫组织化学研究，并将组织制成市售组织芯片。
三级医疗中心。
采用标准免疫组织化学方法，用抗半乳糖凝集素-3、β-连环蛋白和细胞周期蛋白D1的单克隆抗体对甲状腺组织芯片进行染色。
半乳糖凝集素-3的核表达和胞质表达与临床参数、β-连环蛋白和细胞周期蛋白D1表达的相关性。
多数恶性肿瘤中均观察到胞质（56%）和核（42%）半乳糖凝集素-3表达，而良性甲状腺标本中未观察到（P<0.001）。在癌组织中，甲状腺乳头状癌（82%）、滤泡状癌（33%）和髓样癌（9%）中观察到胞质半乳糖凝集素-3表达，而未分化癌中未观察到（P<0.001）。甲状腺乳头状癌（62%）和滤泡状癌（33%）中观察到半乳糖凝集素-3核表达，而髓样癌和未分化癌中未检测到（P<0.001）。胞质而非核半乳糖凝集素-3与美国癌症联合委员会TNM分期呈负相关（P = 0.02）。胞质和核β-连环蛋白表达与核（P = 0.04）和胞质（P = 0.003）半乳糖凝集素-3表达均呈强相关。同样，半乳糖凝集素-3核（P<0.001）和胞质（P<0.001）表达与细胞周期蛋白D1表达也呈强相关。
在分化良好的甲状腺肿瘤中，胞质和核半乳糖凝集素-3表达似乎与Wnt信号通路的激活相关，提示半乳糖凝集素-3在甲状腺癌发生中起作用。
